Research programme: oral insulin - Aphios Corporation

Drug Profile

Research programme: oral insulin - Aphios Corporation

Alternative Names: APH-0907; oral insulin - Aphios

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Aphios Corporation
  • Class Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Pancreatic hormone receptor agonists; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Diabetes-mellitus in USA (PO)
  • 20 Oct 2014 Research programme: oral insulin - Aphios Corporation is available for licensing as of 20 Oct 2014. http://www.aphios.com/products/therapeutic-product-pipeline/diabetes/aph-0907.html
  • 17 Dec 2012 Early research in Diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top